Breaking News
February 22, 2019 - New sepsis test could save thousands of lives
February 22, 2019 - Cervical cancer could be eradicated by 2100
February 21, 2019 - Sustained smoking cessation can lower risk of seropositive RA
February 21, 2019 - Thousands with chronic UTIs are not receiving the treatment they need
February 21, 2019 - Are teens getting high on social media? The surprising study seeking the pot-Instagram link
February 21, 2019 - Stanford expands biobank services | News Center
February 21, 2019 - Scientists identify link between drinking contexts and early onset intoxication among adolescents
February 21, 2019 - Strong social support may reduce cardiovascular disease risk in postmenopausal women
February 21, 2019 - Rapid expansion of interventions could prevent up to 13 million cases of cervical cancer within 50 years
February 21, 2019 - Motif Bio Receives Complete Response Letter From The FDA
February 21, 2019 - Researchers map previously unknown disease in children
February 21, 2019 - A skeptical look at popular diets: Going gluten-free
February 21, 2019 - Podcast: KHN’s ‘What The Health?’ How Safe Are Your Supplements?
February 21, 2019 - Anticipatory signals in eye movements can help measure attentive capacity, learning with greater precision
February 21, 2019 - Evening exercise does not negatively affect sleep, may also reduce hunger
February 21, 2019 - Artificial intelligence technique can be used to identify alcohol misuse in trauma setting
February 21, 2019 - Overweight, obesity in adolescence associated with increased risk of renal cancer later in life
February 21, 2019 - BGU develops new AI platform for monitoring and predicting ALS progression
February 21, 2019 - Researchers discover a new promising target to improve HIV vaccines
February 21, 2019 - Brief Anesthesia in Infancy Does Not Mar Neurodevelopment
February 21, 2019 - Gaming system helps with autism diagnosis
February 21, 2019 - Heart Disease: Six Things Women Should Know
February 21, 2019 - More States Say Doctors Must Offer Overdose Reversal Drug Along With Opioids
February 21, 2019 - Researchers explore case studies focused on industries that kill more people than employed
February 21, 2019 - Only half of GP practice buildings are fit for purpose
February 21, 2019 - Intense exercise, fasting and hormones can enhance waste-protein removal, study shows
February 21, 2019 - Scientists can monitor brain activity to predict epileptic seizures few minutes in advance
February 21, 2019 - Study quantifies hepatic and intestinal mRNA expression of Ugt isoforms in rats
February 21, 2019 - ‘Apple-Shaped’ Body? ‘Pear-Shaped’? Your Genes May Tell
February 21, 2019 - Can we repair the brain? The promise of stem cell technologies for treating Parkinson’s disease
February 21, 2019 - Trump Plan To Beat HIV Hits Rough Road In Rural America
February 21, 2019 - PENTAX Medical introduces new electrosurgical and argon plasma coagulation platforms
February 21, 2019 - Trump plan to beat HIV hits rough road in rural America
February 21, 2019 - Eating blueberries every day could help decrease blood pressure
February 21, 2019 - ‘No Second Chances’ report calls for new measures to combat cardiovascular disease in Australia
February 21, 2019 - Mayo clinic researchers discuss local case studies of leprosy
February 21, 2019 - Scientists demonstrate key role of salt in allergic immune reactions
February 21, 2019 - Experts propose revising the criteria for diagnosis of Parkinson’s disease
February 21, 2019 - The med student and the machine
February 21, 2019 - Hey, Hey! Ho, Ho! Is Striking For School Nurses The Way To Go?
February 21, 2019 - Latest research encourages children to move out and learn through physical activity
February 21, 2019 - Proper oral hygiene and regular visits to dentist can promote heart health
February 21, 2019 - New, versatile technique for remote control of transplanted cells in Parkinson’s
February 21, 2019 - Why melanoma tumors in the brain may be worse?
February 21, 2019 - New project aims to improve lung disease care in Appalachia
February 21, 2019 - Drug increases melanin production in some people with albinism
February 21, 2019 - Over 1 in 3 adults miss the mark on protein, finds study
February 21, 2019 - CymaBay Therapeutics Announces Seladelpar Granted Breakthrough Therapy Designation by the FDA for the Treatment of Primary Biliary Cholangitis
February 21, 2019 - A correlation between obesity and income has only developed in the past 30 years
February 21, 2019 - Baby, then work: An effort to help resident-parents in emergency medicine
February 21, 2019 - Heavy cigarette smoking could damage vision, say researchers
February 21, 2019 - Some drug combinations may be more effective than others for schizophrenic patients
February 21, 2019 - Combination of common antibiotics can eliminate multi-drug resistant E. coli
February 21, 2019 - Number of calls to U.S. Poison Control regarding kratom exposure increased
February 21, 2019 - New computational tool searches for factors that cause specific diseases
February 21, 2019 - New method to assess effectiveness of psychotherapies for social anxiety disorder
February 21, 2019 - New technology measures hormones that influence reproductive health efficiently
February 21, 2019 - Bat influenza viruses could potentially attack the cells of humans and livestock
February 21, 2019 - Immunotherapeutic antibody therapy to kill cancer has now progressed to patient testing
February 21, 2019 - Johns Hopkins scientists find new compound that may prevent reperfusion injury
February 21, 2019 - Researchers develop new way to deliver treatment for cartilage regeneration
February 21, 2019 - Study sheds new light on left ventricular dysfunction in ischemic heart disease
February 21, 2019 - New technique could expedite cancer diagnosis, lead to better patient outcomes
February 21, 2019 - New map of infant brain may aid early diagnosis of autism
February 21, 2019 - Human consciousness depends on the brain’s ability to maintain dynamics of neural activity
February 21, 2019 - Harmony Biosciences Announces File Acceptance Of Its New Drug Application For Pitolisant
February 21, 2019 - Medications could fill treatment gap for adolescents with obesity
February 21, 2019 - New antibiotics are desperately needed: Machine learning could help | News Center
February 21, 2019 - Researchers develop new computer game for dementia carers
February 21, 2019 - University of Dundee partners with Takeda to develop new treatments for tau pathology
February 21, 2019 - Influenza vaccine may be less effective in elderly patients, finds study
February 21, 2019 - Researchers explain why T cells lose their protective ability in inflamed tissues
February 21, 2019 - New optimization method rapidly analyzes nanomedicines for cancer treatment
February 21, 2019 - Viruses in the intestinal tracts can lead to islet autoimmunity and Type 1 diabetes
February 21, 2019 - Link between dietary fatty acid intake and hypertension found to be influenced by diabetes status
February 21, 2019 - FDA Approves Esperoct (turoctocog alfa pegol, N8-GP) for Hemophilia A
February 21, 2019 - ‘Boy erased’—why conversion therapies and ex-gay ministries should be outlawed
February 21, 2019 - Titia de Lange to give annual McCormick Lecture on March 8 | News Center
February 21, 2019 - Study reveals how helper T cells support memory cells to function optimally
February 21, 2019 - Autistic children with co-occurring ADHD have greater adaptive behavior impairments

The Current issue of “The view from here” is concerned with Novel Targets.

image_pdfDownload PDFimage_print

Well, by the time this article is sent out we will know the winners of the 2018 World Cup. I do now know that it won’t be England, which gives me the opportunity more fully to concentrate on the more important (some would say) business of drug discovery. Easy to say that when you have lost, I suppose. In any case, the theme for this month’s newsletter offering is “Novel Targets” and selecting articles for this represents just as difficult a prospect as that of naming the winner of the World Cup, although I might point out that none of the articles in this mailing are from either Croatia nor France, in strict adherence with the Drug Discovery Today policy of impartiality. Selecting articles to highlight the topic of Novel Targets is difficult in that they need to be sufficiently early stage to represent good areas for research for drugs for unmet clinical need, yet sufficiently mature that they have a good likelihood of success, with respect to the ability to modify pathological processes with good druggability as viewed from PK/ PD or medicinal chemistry perspective. As in sport, everyone has their own view on “Novel Targets” and I hope that you agree with my choices or, at least, that it sparks some comment or discussion.  

 

The first article in this month’s offering is entitled: “Molecular epigenetic targets for liver diseases: current challenges and future prospects”, by Robert Zeidler, Bruno Leonardo de Freitas Soares, Augustinus Bader and Shibashish Giri of Leipzig and Munich, Germany. In this article, the authors highlight, not a single target, but a potential group of novel targets for liver diseases that derive from epigenetic approaches. The article demonstrates how epigenetics can inevitably represent excellent leads for the treatment of liver diseases, not least hepatocellular carcinoma. The advantages of modifying gene expression without changing DNA sequence or blocking are highlighted in the review. Clearly, modulation of the epigenome may represent a great step forward for the treatment of liver diseases that currently represent a massive unmet clinical need. 

 

The second article in the series deals with approaches to the treatment of a disease that affects a very different population than the first. It is by Vineet Jain and Keerti Jain of the Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, India  and is entitled: “Molecular targets and pathways for the treatment of visceral leishmaniasis”. Currently, the treatment of leishmaniasis is hampered by the development of resistance to current “gold standard” first line drugs (and their inherent toxicity). Also, in many and other approaches are not available. For example, a clinically-approved vaccine for the disease is not yet available. Moreover, as this disease is most prominent in underdeveloped and developing countries, cost is a major factor as is the availability of suitable infrastructure to support, for example, a vaccine-led approach. This article deals with the approach to molecular targets within the parasite itself that may represent useful approaches to the treatment of this serious tropical disease.

 

And finally, we highlight an article from Vanessa Abella, Jesús Pino, Morena Scotece, Javier Conde, Francisca Lago, Miguel Angel Gonzalez-Gay, Antonio Mera, Rodolfo Gómez, Ali Mobasheri and Oreste Gualillo entitled: “Progranulin as a biomarker and potential therapeutic agent” In contrast with the previous article the identification of progranulin as a potential target addresses diseases that are firmly ensconced in the developed world. Progranulin has been established as being a major participant in inflammation and tumorigenesis since its initial discovery as an adipokine involved in diverse signaling processes impacting obesity, insulin resistance and rheumatic arthritides. The article gives a wonderful overview of the current scientific literature related to its validity as a therapeutic target. Should its potential be realized, then it is possible that drugs could be developed that could address fields as diverse as cancer, neurodegenerative disease and rheumatology.

 

 

Steve Carney was born in Liverpool, England and studied Biochemistry at Liverpool University, obtaining a BSc.(Hons) and then read for a PhD on the Biochemistry and Pathology of Connective Tissue Diseases in Manchester University, in the Departments of Medical Biochemistry and Histopathology. On completion of his PhD he moved to the Kennedy Institute of Rheumatology, London, where he worked with Professor Helen Muir FRS and Professor Tim Hardingham, on the biochemistry of experimental Osteoarthritis. He joined Eli Lilly and Co. and held a number of positions in Biology R&D, initially in the Connective Tissue Department, but latterly in the Neuroscience Department. He left Lilly to take up his present position as Managing Editor, Drug Discovery Today, at Elsevier. Currently, he also holds an honorary lectureship in Drug Discovery at the University of Surrey, UK. He has authored over 50 articles in peer-reviewed journals, written several book chapters and has held a number of patents. 

Tagged with:

About author

Related Articles